The effects of signal transducer and activator of transcription three mutations on human platelets

References

• Villarino AV, Kanno Y, Ferdinand JR, O’Shea JJ. Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol 2015;194:21–27.
   PubMed Web of Science ®Google Scholar
• Vogel TP, Milner JD, Cooper MA. The Ying and Yang of STAT3 in human disease. J Clin Immunol 2015;35:615–623.
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol 2009;27:485–517.
   PubMed Web of Science ®Google Scholar
• Lu D, Liu L, Ji X, Gao Y, Chen X, Liu Y, Liu Y, Zhao X, Li Y, Li Y, et al. The phosphatase DUSP2 controls the activity of the transcription activator STAT3 and regulates TH17 differentiation. Nat Immunol 2015;16:1263–1273.
   PubMed Web of Science ®Google Scholar
• Banerjee K, Resat H. Constitutive activation of STAT3 in breast cancer cells: a review. Int J Cancer 2016;138:2570–2578.
   PubMed Web of Science ®Google Scholar
• Peyser ND, Freilino M, Wang L, Zeng Y, Li H, Johnson DE, Grandis JR. Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer. Oncogene 2016;35:1163–1169.
   PubMed Web of Science ®Google Scholar
• Haapaniemi EM, Kaustio M, Rajala HL, Van Adrichem AJ, Kainulainen L, Glumoff V, Doffinger R, Kuusanmaki H, Heiskanen-Kosma T, Trotta L, et al. Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3. Blood 2015;125:639–648.
   PubMed Web of Science ®Google Scholar
• Gao W, McCormick J, Connolly M, Balogh E, Veale DJ, Fearon U. Hypoxia and STAT3 signalling interactions regulate pro-inflammatory pathways in rheumatoid arthritis. Ann Rheum Dis 2015;74:1275–1283.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Gushiken FC, Bolgiano D, Salsbery BJ, Aghakasiri N, Jing N, Wu X, Vijayan KV, Rumbaut RE, Adachi R, et al. Signal transducer and activator of transcription 3 (STAT3) regulates collagen-induced platelet aggregation independently of its transcription factor activity. Circulation 2013;127:476–485.
   PubMed Web of Science ®Google Scholar
• Yuan H, Houck KL, Tian Y, Bharadwaj U, Hull K, Zhou Z, Zhu M, Wu X, Tweardy DJ, Romo D, et al. Piperlongumine blocks JAK2-STAT3 to inhibit collagen-induced platelet reactivity independent of reactive oxygen species. PLoS One 2015;10:e0143964.
   PubMed Web of Science ®Google Scholar
• Lu WJ, Lin KC, Huang SY, Thomas PA, Wu YH, Wu HC, Lin KH, Sheu JR. Role of a Janus kinase 2-dependent signaling pathway in platelet activation. Thromb Res 2014;133:1088–1096.
   PubMed Web of Science ®Google Scholar
• Grozovsky R, Begonja AJ, Liu K, Visner G, Hartwig JH, Falet H, Hoffmeister KM. The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. Nat Med 2015;21:47–54.
   PubMed Web of Science ®Google Scholar
• Hsu AP, Davis J, Puck JM, Holland SM, Freeman AF. Autosomal dominant hyper IgE syndrome. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017. 2010 Feb 23 [updated 2012 Jun 7].
   Google Scholar
• Mogensen TH. STAT3 and the Hyper-IgE syndrome: clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties. Jakstat 2013;2:e23435.
   PubMedGoogle Scholar
• Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, Hara T, Kawamura N, Ariga T, Pasic S, Stojkovic O, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007;448:1058–1062.
   PubMed Web of Science ®Google Scholar
• Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, Freeman AF, Demidowich A, Davis J, Turner ML, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 2007;357:1608–1619.
   PubMed Web of Science ®Google Scholar
• Van De Veerdonk FL, Marijnissen RJ, Joosten LA, Kullberg BJ, Drenth JP, Netea MG, Van Der Meer JW. Milder clinical hyperimmunoglobulin E syndrome phenotype is associated with partial interleukin-17 deficiency. Clin Exp Immunol 2010;159:57–64.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wu J, Peng X, Song J, Wang J, Dong W. Associations between STAT3 rs744166 polymorphisms and susceptibility to ulcerative colitis and Crohn’s disease: a meta-analysis. PLoS One 2014;9:e109625.
   PubMedGoogle Scholar
• Ferguson LR, Han DY, Fraser AG, Huebner C, Lam WJ, Morgan AR, Duan H, Karunasinghe N. Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn’s disease in a New Zealand population. Mutat Res 2010;690:108–115.
   PubMed Web of Science ®Google Scholar
• Kotkowska A, Sewerynek E, Domanska D, Pastuszak-Lewandoska D, Brzezianska E. Single nucleotide polymorphisms in the STAT3 gene influence AITD susceptibility, thyroid autoantibody levels, and IL6 and IL17 secretion. Cell Mol Biol Lett 2015;20:88–101.
   PubMed Web of Science ®Google Scholar
• Netea MG, Joosten LA, Li Y, Kumar V, Oosting M, Smeekens S, Jaeger M, Ter Horst R, Schirmer M, Vlamakis H, et al. Understanding human immune function using the resources from the human functional genomics project. Nat Med 2016;22:831–833.
   PubMed Web of Science ®Google Scholar
• Ter Horst R, Jaeger M, Smeekens SP, Oosting M, Swertz MA, Li Y, Kumar V, Diavatopoulos DA, Jansen AF, Lemmers H, et al. Host and environmental factors influencing individual human cytokine responses. Cell 2016;167:1111-1124:e1113.
   Web of Science ®Google Scholar
• Li Y, Oosting M, Deelen P, Ricano-Ponce I, Smeekens S, Jaeger M, Matzaraki V, Swertz MA, Xavier RJ, Franke L, et al. Inter-individual variability and genetic influences on cytokine responses to bacteria and fungi. Nat Med 2016;22:952–960.
   PubMed Web of Science ®Google Scholar
• Yang XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS, Dong C. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 2007;282:9358–9363.
   PubMed Web of Science ®Google Scholar
• Shah TS, Liu JZ, Floyd JA, Morris JA, Wirth N, Barrett JC, Anderson CA. optiCall: a robust genotype-calling algorithm for rare, low-frequency and common variants. Bioinformatics 2012;28:1598–1603.
   PubMed Web of Science ®Google Scholar
• Semple JW, Italiano JE Jr., Freedman J. Platelets and the immune continuum. Nat Rev Immunol 2011;11:264–274.
   PubMed Web of Science ®Google Scholar
• Wu D, Xie J, Wang X, Zou B, Yu Y, Jing T, Zhang S, Zhang Q. Micro-concentration lipopolysaccharide as a novel stimulator of megakaryocytopoiesis that synergizes with IL-6 for platelet production. Sci Rep 2015;5:13748.
   PubMed Web of Science ®Google Scholar
• Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, Theurl I, Widder W, Molnar C, Ludwiczek O, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 2001;98:2720–2725.
   PubMed Web of Science ®Google Scholar
• Wegrzyn J, Potla R, Chwae YJ, Sepuri NB, Zhang Q, Koeck T, Derecka M, Szczepanek K, Szelag M, Gornicka A, et al. Function of mitochondrial STAT3 in cellular respiration. Science 2009;323:793–797.
   PubMed Web of Science ®Google Scholar
• Visavadiya NP, Keasey MP, Razskazovskiy V, Banerjee K, Jia C, Lovins C, Wright GL, Hagg T. Integrin-FAK signaling rapidly and potently promotes mitochondrial function through STAT3. Cell Commun Signal 2016;14:32.
   PubMed Web of Science ®Google Scholar
• Woollard KJ, Suhartoyo A, Harris EE, Eisenhardt SU, Jackson SP, Peter K, Dart AM, Hickey MJ, Chin-Dusting JP. Pathophysiological levels of soluble P-selectin mediate adhesion of leukocytes to the endothelium through Mac-1 activation. Circ Res 2008;103:1128–1138.
   PubMed Web of Science ®Google Scholar
• Chandesris MO, Azarine A, Ong KT, Taleb S, Boutouyrie P, Mousseaux E, Romain M, Bozec E, Laurent S, Boddaert N, et al. Frequent and widespread vascular abnormalities in human signal transducer and activator of transcription 3 deficiency. Circ Cardiovasc Genet 2012;5:25–34.
   PubMed Web of Science ®Google Scholar
• Dutzmann J, Daniel JM, Bauersachs J, Hilfiker-Kleiner D, Sedding DG. Emerging translational approaches to target STAT3 signalling and its impact on vascular disease. Cardiovasc Res 2015;106:365–374.
   PubMed Web of Science ®Google Scholar
• Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet 2012;380:2095–2128.
   PubMed Web of Science ®Google Scholar
• Wake MS, Watson CJ. STAT3 the oncogene - still eluding therapy? Febs J 2015;282:2600–2611.
   PubMed Web of Science ®Google Scholar
• Huang W, Dong Z, Chen Y, Wang F, Wang CJ, Peng H, He Y, Hangoc G, Pollok K, Sandusky G, et al. Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo. Oncogene 2016;35:783–792.
   PubMed Web of Science ®Google Scholar
• Oh DY, Lee SH, Han SW, Kim MJ, Kim TM, Kim TY, Heo DS, Yuasa M, Yanagihara Y, Bang YJ. Phase I study of OPB-31121, an oral STAT3 inhibitor, in patients with advanced solid tumors. Cancer Res Treat 2015;47:607–615.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 2015;372:426–435.
   PubMed Web of Science ®Google Scholar
• Goel D. Ticagrelor: the first approved reversible oral antiplatelet agent. Int J Appl Basic Med Res 2013;3:19–21.
   PubMedGoogle Scholar
• Marczewski MM, Postula M, Kosior D. Novel antiplatelet agents in the prevention of cardiovascular complications–focus on ticagrelor. Vasc Health Risk Manag 2010;6:419–429.
   PubMedGoogle Scholar
• Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, Pascal M, Herbert JM. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000;84:891–896.
   PubMed Web of Science ®Google Scholar
• Abdulmalak C, Cottenet J, Beltramo G, Georges M, Camus P, Bonniaud P, Quantin C. Haemoptysis in adults: a 5-year study using the French nationwide hospital administrative database. Eur Respir J 2015;46:503–511.
   PubMed Web of Science ®Google Scholar
• Lee BR, Yu JY, Ban HJ, Oh IJ, Kim KS, Kwon YS, Kim YI, Kim YC, Lim SC. Analysis of patients with hemoptysis in a tertiary referral hospital. Tuberc Respir Dis (Seoul) 2012;73:107–114.
   PubMedGoogle Scholar
• Benekli M, Baer MR, Baumann H, Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood 2003;101:2940–2954.
   PubMed Web of Science ®Google Scholar
• Grimbacher B, Holland SM, Gallin JI, Greenberg F, Hill SC, Malech HL, Miller JA, O’Connell AC, Puck JM. Hyper-IgE syndrome with recurrent infections–an autosomal dominant multisystem disorder. N Engl J Med 1999;340:692–702.
   PubMed Web of Science ®Google Scholar